Very solid result on the revenue side and the US business is showing how robust it is and that the strong growth rates in CBD are contuing to accelerate.
It is good to see that they company is investing for growth in both Supply and sales and marketing in multiple markets.
There is no point sitting around waiting for a Medical marijuana licence in Australia when you have a great business in the US that you can invest in to accelerate growth.
All of this is before hemp is fully legalised in the US at a federal level..That could really turbocharge the adoption of CBD products.
I reckon we will see renewed interest in the shares as it comes on more funds radar..still very little retail interest.
An upgrade from Bell potter to $2.31 price target based on revenues ahead of forecast should help too.
Patience will be rewarded with this stock.
Ann: Quarterly Report and Appendix 4C, page-7
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.605M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.605K | 321.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 6265944 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 14532474 | 10 |
View Market Depth
| Last trade - 15.57pm 25/11/2024 (20 minute delay) ? |
| EXL (ASX) Chart |
